1026 related articles for article (PubMed ID: 17555947)
41. Aripiprazole: a review of its use in the management of schizophrenia in adults.
Croxtall JD
CNS Drugs; 2012 Feb; 26(2):155-83. PubMed ID: 22296317
[TBL] [Abstract][Full Text] [Related]
42. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
43. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
44. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Chan HY; Lin WW; Lin SK; Hwang TJ; Su TP; Chiang SC; Hwu HG
J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
[TBL] [Abstract][Full Text] [Related]
46. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
47. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
48. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
49. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
Christensen AF; Poulsen J; Nielsen CT; Bork B; Christensen A; Christensen M
Acta Psychiatr Scand; 2006 Feb; 113(2):148-53. PubMed ID: 16423167
[TBL] [Abstract][Full Text] [Related]
50. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T
Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864
[TBL] [Abstract][Full Text] [Related]
51. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
52. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
53. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
[TBL] [Abstract][Full Text] [Related]
54. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Marcus RN; Owen R; Manos G; Mankoski R; Kamen L; McQuade RD; Carson WH; Findling RL
J Clin Psychiatry; 2011 Sep; 72(9):1270-6. PubMed ID: 21813076
[TBL] [Abstract][Full Text] [Related]
55. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
56. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
[TBL] [Abstract][Full Text] [Related]
57. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
Glick ID; Poyurovsky M; Ivanova O; Koran LM
J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Zhang Y; Dai G
Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
[TBL] [Abstract][Full Text] [Related]
59. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study.
Vieta E; T'joen C; McQuade RD; Carson WH; Marcus RN; Sanchez R; Owen R; Nameche L
Am J Psychiatry; 2008 Oct; 165(10):1316-25. PubMed ID: 18381903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
